Stalevo | 745835-09-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Stalevo
• 英文别名: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide;(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
• CAS: 745835-09-0
• 化学式: C33H40N6O13
• 分子量: 728.7
• InChiKey: OTVUCEMFRGJEMR-FTXVUGNJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.78
• 重原子数：
  52
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  350
• 氢给体数：
  11
• 氢受体数：
  17

文献信息

• Levodopa carbidopa entacapone pharmaceutical formulations
  申请人：Deva Holding Anonim Sirketi

  公开号：EP2799065A1

  公开（公告）日：2014-11-05

  The present invention relates to a new pharmaceutical composition of entacapone, levodopa and carbidopa or pharmaceutically acceptable or hydrates thereof characterized in that characterized in that it comprises; a) a first granule wherein 90 % by weight of the total amount of levodopa is mixed with 90 % by weight of the total amount of carbidopa and 10% by weight of the total amount of entacapone, optionally in the presence of pharmaceutical acceptable excipients. b) a second granule wherein 10 % by weight of the total amount of levodopa is mixed with 10 % by weight of the total amount of carbidopa and 90% by weight of the total amount of entacapone, optionally in the presence of pharmaceutical acceptable excipients. c) Optionally mixed other pharmaceutically acceptable excipients, d) coating of core tablets is composed of hydroxypropyl cellulose and hydroxypropyl methyl cellulose.

  本发明涉及一种新的恩他卡朋、左旋多巴和卡比多巴或其药学上可接受的或水合物的药物组合物，其特征在于它包括：a)第一种颗粒剂，其中左旋多巴总量的90％(重量)与卡比多巴总量的90％(重量)和恩他卡朋总量的10％(重量)混合，可选择在有药学上可接受的赋形剂存在的情况下。b) 第二种颗粒剂，其中左旋多巴总量的 10%（重量百分比）与卡比多巴总量的 10%（重量百分比）和恩他卡彭总量的 90%（重量百分比）混合，可选择在有药学上可接受的赋形剂存在的情况下。 c) 可选择混合其他药学上可接受的赋形剂， d) 芯片的包衣由羟丙基纤维素和羟丙基甲基纤维素组成。
• Combinatorial synthesis and biomarker development
  申请人：Moola Muralidhar Reddy

  公开号：US10458995B2

  公开（公告）日：2019-10-29

  Provided herein are methods, kits, and compositions for use in the diagnosis and treatment of diseases. Peptoids recognized by Alzheimers disease specific antibodies are identified.

  本文提供了用于诊断和治疗疾病的方法、试剂盒和组合物。鉴定了阿尔茨海默病特异性抗体识别的蛋白胨。
• Identification of dysregulated genes in patients with neurological diseases
  申请人：Scherzer R. Clemens

  公开号：US20060134664A1

  公开（公告）日：2006-06-22

  The present invention identifies a number of gene markers whose expression is altered in neurodegenerative diseases (ND). These markers can be used to diagnose or predict ND in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent ND development or progression.

  本发明确定了一些在神经退行性疾病（ND）中表达发生改变的基因标记物。这些标记可用于诊断或预测受试者的 ND，并可用于监测疗法。此外，这些基因还能确定治疗靶点，改变这些靶点可预防 ND 的发展或恶化。
• COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT
  申请人：Moola, Muralidhar Reddy

  公开号：EP3433262A1

  公开（公告）日：2019-01-30
• IDENTIFICATION OF SMALL MOLECULES RECOGNIZED BY ANTIBODIES IN SUBJECTS WITH NEURODEGENERATIVE DISEASES
  申请人：Moola Muralidhar Reddy

  公开号：US20100303805A1

  公开（公告）日：2010-12-02

  The present invention provides for the identification of individuals having neurodegenerative diseases (ND). Peptoids recognized by Parkinson's Disease- and Alzheimer's Disease-specific antibodies are identified, allowing one to diagnose or predict ND in subjects.